Current therapy strategy for metastatic BRAF-positive skin melanoma
- Authors: Polyakov A.P1, Mordovsky A.V.1
-
Affiliations:
- P.A. Hertsen Moscow Oncology Research Institute - Branch of the National Medical Research Radiological Center
- Issue: Vol 27, No 11 (2020)
- Pages: 14-20
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/312869
- DOI: https://doi.org/10.18565/pharmateca.2020.11.14-20
- ID: 312869
Cite item
Abstract
This review summarizes data from studies on the use of a combination of targeted drugs in the treatment of metastatic BRAF-positive skin melanoma. The addition of a MEK inhibitor to a BRAF inhibitor slows tumor growth, delays acquired resistance, and inhibits paradoxical activation of the MAPK pathway in patients with melanoma and BRAF gene mutation.
Full Text
About the authors
A. P Polyakov
P.A. Hertsen Moscow Oncology Research Institute - Branch of the National Medical Research Radiological CenterMoscow, Russia
Aleksandr V. Mordovsky
P.A. Hertsen Moscow Oncology Research Institute - Branch of the National Medical Research Radiological Center
Email: alexmord@live.com
Researcher at the Department of Microsurgery 3, 2nd Botkinsky proezd, Moscow 125284, Russian Federation
References
- de Vries E. Bray F.I. Coebergh J.W. et al. Changing epidemiology of malignant cutaneous melanoma in Europe 1953-1997: rising trends in incidence and mortality but recent stabilizations in western Europe and decreases in Scandinavia. !nt J Cancer. 2003;107:119-26. doi: 10.1002/ijc.11360.
- Siegel R, DeSantis C., Virgo K., et al. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin. 2012;62:220-41. doi: 10.3322/ caac.21149.
- Hodi FS, O’Day S.J., McDermott D.F., et al. improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711-23. doi: 10.1056/ NEJMoa1003466.
- Robert C, Thomas L., Bondarenko i., et al. ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011;364:2517-26. doi: 10.1056/ NEJMoa1104621.
- Wan PIT., Garnett M.J., Roe S.M., et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell. 2004;16(6):855-67. doi: 10.1016/s0092-8674(04)00215-6.
- Davies H, Bignell G.R., Cox C., et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417:949-54. doi: 10.1038/nature00766.
- Ascierto PA, Kirkwood J.M., Grob J.J., et al. The role of BRAF V600 mutation in melanoma. J Transl Med. 2012;10:85. doi: 10.1186/1479-5876-10-85.
- Curtin J.A., Fridlyand J., Kageshita T., et al. Distinct sets of genetic alterations in melanoma. N Engl J Med. 2005;353:2135-47. Doi: 10.1056/ NEJMoa050092.
- Cheng L., Lopez-Beltran A., Massari F, et al. Molecular testing for BRAF mutations to inform melanoma treatment decisions: a move toward precision medicine. Mod Pathol. 2018;31(1):24-38. doi: 10.1038/modpathol.2017.104.
- Клинические рекомендации Министерства Здравоохранения « Мел кожи и слизистых оболочек» 2020 (одобрены НПС при Минздраве России 17 июля 2020 г). Доступно по ссылке: https://melanomapro.ru/uploads/ docs/CR_melanoma_2020_final_compressed. pdf
- Строяковский Д.Л., Абрамов М.Е., Демидов Л.В. и др. Практические рекомендации по лекарственному лечению меланомы кожи. Злокачественные опухоли: Практические рекомендации RUSSCO #3s2. 2019;9:243-58.
- Tsai J., Lee J.T., Wang W., et al. Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc Natl Acad Sci USA. 2008;105(8):3041-46. doi: 10.1073/ pnas.0711741105.
- Bradish J.R., Cheng L. Molecular pathology of malignant melanoma: changing the clinical practice paradigm toward a personalized approach. Hum Pathol 2014;45:1315-26. doi: 10.1016/j. humpath.2014.04.001.
- National Comprehensive Cancer Network (NCCN). Practice Guidelines in Oncology: Melanoma Version 1, Available from: https://www.nccn.org/ professionals/physician_gls/pdf/melanoma.pdf
- Merkel E.A., Gerami P Malignant melanoma of sun-protected sites: a review of clinical, histological, and molecular features. Lab invest. 2017;97:630-doi: 10.1038/labinvest.2016.147.
- Long G.V, Menzies A.M., Nagrial A.M., et al. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J Clin Oncol. 2011;29:1239-46. doi: 10.1200/ JCO.2010.32.4327.
- Chapman PB., Hauschild A., Robert C., et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364:2507-16. doi: 10.1056/ NEJMoa1103782.
- Hauschild A., Grob J.J., Demidov L.V. et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2012;380:358-65. doi: 10.1016/S0140-6736(12)60868-X.
- Chapman PB. Mechanisms of resistance to RAF inhibition in melanomas harboring a BRAF mutation Am Soc Clin Oncol Educ Book. 2013. doi: 10.1200/EdBook_AM.2013.33.e80.
- Shi H., Hugo W., Kong X., et al. Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. Cancer Discov. 2014;4(1):80-doi: 10.1158/2159-8290.CD-13-0642.
- Kim K.B., Kefford R., Pavlick A.C., et al. Phase ii study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor. J Clin Oncol. 2013;31(4):482-89. doi: 10.1200/JCO.2012.43.5966.
- Dhomen N., Marais R. BRAF signaling and targeted therapies in melanoma. Hematol Oncol Clin North Am. 2009;23:529-45. doi: 10.1016/j. hoc.2009.04.001.
- Eroglu Z., Ribas A. Combination therapy with BRAF and MEK inhibitors for melanoma: latest evidence and place in therapy. Ther Adv Med Oncol. 2016;8:48-56.
- Ribas A., Gonzalez R., Pavlick A., et al. Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: a phase 1b study [published correction appears in Lancet Oncol. 2014;15(10):417. Lancet Oncol. 2014;15(9):954-65.
- Paraiso K.H., Fedorenko i.V, Cantini L.P, et al. Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy. Br J Cancer. 2010;102(12):1724-1730. doi: 10.1038/sj.bjc.6605714.
- Larkin J., Ascierto P.A., Dreno B., et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med. 2014;371(20):1867-doi: 10.1056/NEJMoa1408868.
- McArthur, G.A., et al. 5-year survival update of cobimetinib plus vemurafenib BRAF V600 mutation-positive advanced melanoma: final analysis of the coBRIM study. in 16th international Congress of the Society for Melanoma Research. 2019. Salt Lake City, UT, USA.
- Larkin J.M.G., Yan Y, McArthur G.A., Ascierto PA. Update of progression-free survival and correlative biomarker analysis from coBRiM: cobimetinib plus vemurafenib in advanced BRAF-mutated melanoma. ASCO, Chicago, iL, USA. 2015. abstract No9006. URL: http://meetinglibrary.asco. org/node/2002036
- McArthur G.A., Ascierto P.A., Larkin J., Ribas A. LBA5_PR - Phase 3, Double-blind, Placebo-controlled Study of Vemurafenib Versus Vemurafenib+Cobimetinib in Previously Untreated BRAFV600 Mutation-Positive Patients With Unresectable Locally Advanced or Metastatic Melanom. Ann Oncol. 2014; 25(5):1-41.
- Sanlorenzo M., Choudhry A., Vujic i., et al. Comparative profile of cutaneous adverse events: BRAF/MEK inhibitor combination therapy versus BRAF monotherapy in melanoma. J Am Acad Dermatol. 2014;71(6):1102-09.e1. doi: 10.1016/j.jaad.2014.09.002.
- Gutzmer R, Stroyakovskiy D., Gogas H., et al. Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutationpositive melanoma (iMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2020;395:1835-44. doi: 10.1016/ S0140-6736(20)30934-X